In The News
NAB super trustee free to use $165M fees ‘as it saw fit’, class action judge says
Coles, Woolworths say price increases were genuine, and so were the discounts
Dentons says former partner’s equity prospects curtailed by own conduct
Start-up denies ex-Fortescue employees developed green iron on company dime
In class action defence, Toyota says ‘defeat device’ used to protect engines
Maddocks lures leading competition lawyer from Johnson Winter Slattery
Hamilton Locke loses challenge to Sydney law firm’s trade mark
Solve My Debt Now to admit liability in ASIC proceedings
Class action against NAB super fund trustee fails
AI rules to guard against ‘laziness’ in legal profession, top judge says
Please login to bookmarkClose

French pharmaceutical giant Sanofi has appealed a judge’s ruling denying its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au